Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 6/20 | 0.65 |
| ▸ | KCNJ1 | P48048 | 9/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641 | 1.00 | PRF1 (0.65) | PRF1KCNJ1KCNH2MAPTLMNA | |
| Tetrahydrofuran SCHEMBL22089885 | 0.91 | PRF1 (0.56) | PRF1KCNJ1KCNH2MAPTLMNA | |
| Toluene SCHEMBL28417431 | 0.89 | PRF1 (0.55) | PRF1KCNJ1KCNH2MAPTLMNA | |
| SCHEMBL148003 | 0.86 | PRF1 (0.54) | PRF1KCNJ1KCNH2MAPTLMNA | |
| SCHEMBL28914301 | 0.83 | PRF1 (0.59) | PRF1KCNJ1KCNH2MAPTLMNA | |
| SCHEMBL29933676 | 0.83 | PRF1 (0.59) | PRF1KCNJ1KCNH2MAPTLMNA | |
| SCHEMBL22089880 | 0.83 | PRF1 (0.49) | PRF1KCNJ1KCNH2MAPTLMNA | |
| SCHEMBL24442281 | 0.82 | MAPT (0.56) | PRF1KCNJ1KCNH2MAPTLMNA | |
| SCHEMBL13454843 | 0.79 | GRM5 (0.59) | PRF1MAPTLMNAGAAMAOA | |
| SCHEMBL31503953 | 0.79 | PRF1 (0.43) | PRF1KCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3896057-B1 | METHOD FOR CONTINUOUSLY PREPARING CITALOPRAM DIOL | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2023-05-31 | — | — | EP | claimed |
| US-20250092020-A1 | IDO/TDO Inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-03-20 | — | — | US | disclosed |
| EP-4217412-A1 | WASTE MITIGATION METHODS AND MATERIALS | Finite Research Ltd (GB) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022151968-A1 | METHOD FOR PURIFYING KEY INTERMEDIATES OF CITALOPRAM | 浙江华海药业股份有限公司 | 2022-07-21 | — | — | WO | disclosed |
| WO-2022023916-A1 | WASTE MITIGATION METHODS AND MATERIALS | LI, Zhenzhen (CN) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092020-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | PRF1 3914/4885KCNJ1 3877/4885KCNH2 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.